In Q2 2025, we turned strategy into action—advancing multiomics, expanding access to precision oncology, unlocking new AI-powered insights, and supporting national genomics studies like Magic-I in Ireland. It’s been a quarter of meaningful progress and momentum we’re carrying

We're taking comprehensive genomic profiling to the next level. The new TruSight Oncology 500 v2 research assay adds built-in HRD biomarker detection powered by @myriadgenetics, faster turnaround times, and requires less tissue, helping labs accelerate access to critical

At the San Diego Pride Parade, we joined employees, families, and friends to celebrate the community that surrounds and inspires us. 🌈. Every person at Illumina plays a role in advancing our mission to improve human health. We’re thankful to our team—and to iPride, one of our

In the UK, students start making career decisions as young as 12 years old. For many, especially those with limited access to industry exposure and a variety of role models, finding a career path can be challenging. “You cannot be what you cannot see.” – Alison Coffey, Clinical

With the help of Illumina Connected Multiomics and DRAGEN secondary analysis, it’s never been easier to accurately identify methylation events and genetic variants in the same reads with the Illumina 5-base solution:

.@UofLHealth is the first in the U.S. to offer patients TruSight™ Oncology (TSO) Comprehensive—the only FDA-approved test of its kind for solid tumors. This comprehensive assay delivers insights from a single tissue sample, helping care teams identify actionable mutations and

From advanced cancer care to emerging disease research, genomics is making an impact—and Illumina is at the center of it. At @ASCO, Pratheesh Sathyan, Illumina’s Head of AMR Oncology, shared how 25+ years of genomics expertise is driving progress in cancer care.

Fiona Kaper introduces the novel single-step conversion chemistry that sets the Illumina 5-base solution apart from other more complicated methods. Learn how our simplified workflow can help you scale your multiomic studies:

Welcome Mark Field, Illumina’s new Chief Information Officer 📊. In his interview with @Forbes, Mark reflects on the potential of Illumina’s technology, the critical role of IT in advancing R&D, and what inspires him most about the company’s future. Read the full interview:.

The team at @jacksonlab’s Advanced Precision Medicine Lab required a more adaptable and efficient method to manage and interpret intricate genomic data. With the assistance of our Customer Success & Implementation team, they developed a seamless, end-to-end NGS workflow—from.

What’s standing in the way of broader access to genomic innovation in cancer care—and how do we move forward? At @ASCO, Damon Hostin, Sr. Director of Market Access at Illumina, shared how the field is evolving—while addressing gaps in coverage, education, and access to

“Right now, for rare disease, we're diagnosing about one third of cases looking at protein coding sequence alone. So, there must be an explanation for the cases that we're missing,” said Kyle Kai-How Farh MD PhD, VP of the Illumina AI Lab . “We suspect many of them can be.

What are the benefits of adding methylated cytosine, the so-called fifth base, to the standard A, T, G, and C bases in your NGS workflow? Fiona Kaper shares details on the multiomic potential of the new Illumina 5-base solution:

Today, we announced a definitive agreement to acquire SomaLogic, the next step in our multiomics journey. With deep proteomics expertise and a history of collaboration with Illumina, this acquisition will strengthen our ability to deliver end-to-end, scalable insights across

What’s it like to design packaging, install an instrument, or manage big data? Ahead of #InternationalWomeninEngineeringDay, we’re going behind the scenes with three of our talented engineers:

We recently welcomed representatives from the CBRNE Centre of Expertise, a specialized team within the HTX (Home Team Science & Technology Agency), to our Singapore hub for a closer look at our R&D and manufacturing operations. As the first in Singapore to adopt the MiSeq™

Patients and families facing a rare cancer diagnosis deserve timely, actionable answers. At @ASCO, Patient Advocacy Specialist Cody Barnett shared how whole genome sequencing and patient advocacy groups are helping make that possible. #ASCO25

With Illumina 5-base chemistry, it’s now possible to detect genomic and epigenomic insights in a single assay. Fiona Kaper, VP, Head of Assay R&D, shares how this solution overcomes current challenges in multiomics:

At @ASCO, Chief Commercial Officer Everett Cunningham delivered a clear message: every person facing cancer deserves timely, actionable answers no matter where they are in the world. From our global footprint to our growing suite of clinical oncology solutions, we are working to